Compounded GLP-1 Medications: What You Need to Know

What Are Compounded GLP-1 Medications?

Compounded GLP-1 medications are custom-prepared versions of semaglutide or tirzepatide created by licensed pharmacies to meet individual patient needs. Unlike brand-name medications (Ozempic, Wegovy, Mounjaro), compounded drugs are not FDA-approved products. However, they are legal and regulated when prepared under specific conditions.

The FDA permits compounding in two main ways:

• 503A Compounding: Individual pharmacies prepare medications for specific patients based on a doctor's prescription. These are customized, smaller-batch preparations.
• 503B Compounding: Outsourcing facilities manufacture larger quantities for multiple patients without a specific prescription on file. These are more standardized than 503A but still not FDA-approved.

How Compounding Works

Compounding became increasingly common for GLP-1 medications due to significant brand-name shortages. Here's what you need to understand:

The FDA Shortage List

The FDA maintains a Drug Shortages list that tracks which medications are in short supply. When a medication appears on this list, the FDA permits licensed pharmacies to compound alternatives without a pre-existing prescription.

Regulatory Timeline

Semaglutide and tirzepatide shortages began in 2023 due to overwhelming demand for weight-loss use. Compounding became a legal workaround to meet patient demand when brand-name options were unavailable or extremely expensive. As of early 2026, the shortage situation has improved significantly, meaning the FDA's allowance for compounding may be more tightly restricted going forward.

This is an important context: compounded GLP-1s were created during a genuine supply crisis. Your prescription will still be valid if your doctor prescribes a compounded formulation, but you should understand that these are not the same as brand-name products in terms of regulatory oversight or supply guarantees.

The FDA Shortage Situation: What Changed

In late 2023 and early 2024, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages were critical. Manufacturing couldn't keep pace with demand. This is what enabled compounding to flourish.

By early 2026, the shortage has eased considerably:

• Brand-name supply has improved, though prices remain high.
• FDA guidance on compounding has become more restrictive — compounding is now more strictly limited to genuine shortages or specific circumstances.
• Insurance coverage has expanded slightly, making brand-name options more accessible for some patients.
• The market has normalized, reducing the urgency that drove earlier compounding demand.

The upshot: compounded GLP-1s remain available, but the justification for using them has shifted. They're now more for cost-sensitive patients or those with specific dosing needs, rather than as an emergency shortage solution.

Compounded vs Brand-Name: Key Differences

Understanding the distinctions helps you make an informed choice:

Factor	Brand-Name (Wegovy, Ozempic)	Compounded
FDA Approval	Fully FDA-approved	Not FDA-approved; prepared under FDA oversight during shortages
Cost	$900–1,300/month (often covered by insurance)	$69–199/month (rarely covered by insurance)
Insurance Coverage	Possible with prior authorization	Almost never covered; out-of-pocket only
Supply Consistency	Consistent manufacturing standards	Varies by pharmacy; less rigorous quality control
Dosing Flexibility	Standard doses only	Custom doses available (e.g., 1.2 mg, 2.0 mg, 2.5 mg)
Active Ingredient Source	Novo Nordisk (semaglutide) or Eli Lilly (tirzepatide)	Bulk powder from various suppliers; quality varies
Shelf Life / Stability	Tested and guaranteed	Varies; typically 30–60 days in some formulations

Cost Comparison

Cost is often the primary driver for choosing compounded GLP-1s. Here's what patients typically pay (as of March 2026):

• Compounded Semaglutide: $69–199 per month (depending on dose and pharmacy).
• Brand-Name Wegovy: ~$1,300 per month (uninsured); covered by some insurance plans.
• Brand-Name Ozempic: ~$900 per month (uninsured); often covered for diabetes but not weight loss.
• Compounded Tirzepatide: $99–249 per month (less widely available than compounded semaglutide).
• Brand-Name Mounjaro/Zepbound: ~$1,350 per month (uninsured); emerging insurance coverage.

The cost difference is stark: compounded options cost 85–95% less than brand-name versions. However, this comes with tradeoffs in regulatory oversight and supply consistency.

Programs Offering Compounded GLP-1s

Several telehealth and direct-to-patient programs now offer compounded semaglutide and tirzepatide. Here are the main players:

Safety Considerations

Choosing compounded GLP-1s carries real health considerations. Here's what you should verify:

Red Flags to Avoid

Be cautious of:

• No prescription required: Legitimate compounding always requires a doctor's prescription.
• Prices that seem too good to be true: Under $50/month is a warning sign of poor quality or unlicensed operation.
• Overseas shipping: Compounded medications shipped from international sources bypass FDA oversight entirely.
• No pharmacist availability: Reputable services have licensed pharmacists available for questions.
• Claims of "FDA-approved compounding": Compounding itself is never FDA-approved; only the active ingredient can be.

Who Should Consider Compounded GLP-1s?

Good Candidates

• Patients without insurance or with plans that don't cover weight-loss GLP-1s.
• Those who need non-standard dosing (e.g., you prefer 2.0 mg instead of the standard 1.7 mg).
• Individuals who've experienced shortages of brand-name medications.
• Cost-sensitive patients for whom the price difference ($900 vs $99/month) is life-changing.
• People with specific allergies or sensitivities to brand-name formulation ingredients.

Poor Candidates

• Patients with comprehensive insurance that covers brand-name GLP-1s. Use your coverage.
• Those uncomfortable with non-FDA-approved medication status. That's a valid concern.
• Anyone who cannot access reliable pharmacist support or ongoing care coordination.
• Patients with complex medical histories who benefit from the strict oversight brand-name medications receive.

Frequently Asked Questions